Health Canada Approves Biogen Idec’s Long-Acting ALPROLIX™ Therapy for Hemophilia B

Friday, March 21, 2014 1 min read

Key Takeaway: Health Canada Approves Biogen Idec’s Long-Acting ALPROLIX™ Therapy for Hemophilia B

Full Press Release Details

Health Canada Approves Biogen Idec’s Long-Acting ALPROLIX™ Therapy for Hemophilia B.